News from cepheid A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Mar 24, 2015, 16:05 ET

Cepheid Receives Emergency Use Authorization from FDA for Xpert Ebola Diagnostic Test

 Cepheid (Nasdaq: CPHD) today announced it has received Emergency Use Authorization from the U.S. Food & Drug Administration (FDA) for...

Mar 24, 2015, 07:00 ET

On World TB Day 2015 Cepheid and NHLS Commemorate Global Shipment of the 10 Millionth Xpert MTB/RIF Test Cartridge

 Cepheid (Nasdaq: CPHD) and the National Health Laboratory Service (NHLS) in South Africa today recognized World TB Day 2015 by commemorating...

Feb 18, 2015, 16:05 ET

Cepheid to Webcast Upcoming Financial Presentations

 Cepheid (NASDAQ: CPHD) today announced that its executives will be speaking at the following conferences, and invited investors to participate...

Feb 13, 2015, 07:00 ET

Cepheid Receives FDA Clearance for Expanded Claims on Tuberculosis Test

 Cepheid (Nasdaq: CPHD) today announced it has received clearance from the U.S. Food & Drug Administration (FDA) for expanded claims on its...

Jan 29, 2015, 16:05 ET

Cepheid Reports Fourth Quarter And Full Year 2014 Results

 Cepheid (Nasdaq: CPHD) today reported revenue for the fourth quarter of 2014 of $131.5 million.  Net...

Jan 05, 2015, 08:00 ET

Cepheid Announces CFO Change

Cepheid (Nasdaq: CPHD) today announced that Andrew Miller, executive vice president and chief financial officer, will be leaving Cepheid to pursue...

Dec 29, 2014, 07:00 ET

Cepheid and FIND Announce European Approval of Xpert HIV-1 Viral Load

Cepheid (Nasdaq: CPHD) and the Foundation for Innovative New Diagnostics (FIND) today announced that Xpert® HIV-1 Viral Load, a quantitative...

Dec 01, 2014, 07:00 ET

Cepheid Receives FDA Clearance for Xpert Norovirus, the First On-Demand Molecular Test for Detection of Norovirus

Cepheid (NASDAQ: CPHD) today announced it has received clearance from the U.S. Food & Drug Administration (FDA) to market Xpert®...

Nov 24, 2014, 16:05 ET

Cepheid Receives FDA Clearance for Xpert Flu/RSV XC

Cepheid (NASDAQ: CPHD) today announced it has received clearance from the U.S. Food & Drug Administration (FDA) to market its Xpert®...

Nov 20, 2014, 16:05 ET

Cepheid to Webcast Upcoming Financial Presentations

 Cepheid (NASDAQ: CPHD) today announced that its executives will be speaking at the following conferences, and invited investors to participate...

Nov 13, 2014, 07:00 ET

Cepheid To Develop Xpert Ebola For Countries Worst Hit By Epidemic

 Cepheid (NASDAQ: CPHD) today announced that it has been awarded a grant of up to $3.3 million co-financed by the Paul G. Allen Family...

Oct 28, 2014, 07:00 ET

Cepheid, FIND & Rutgers Announce Collaboration for Next-Generation Innovations to Game-changing Xpert MTB/RIF Test

 Cepheid (Nasdaq: CPHD), FIND, and Rutgers New Jersey Medical School, today announced details of a collaboration to develop Xpert® MTB/RIF...

Oct 16, 2014, 16:05 ET

Cepheid Reports 2014 Third Quarter Results

 Cepheid (Nasdaq: CPHD) today reported revenues for the third quarter of 2014 of $115.2 million, representing growth of 15% from $100.1 million...

Oct 01, 2014, 16:05 ET

Cepheid Extends Reach Of Direct US Commercial Operations

 Cepheid (NASDAQ: CPHD) today announced that, effective today, it has entered into a purchase agreement to acquire the customer relationships...

Oct 01, 2014, 16:04 ET

Cepheid Schedules 2014 Third Quarter Results Announcement And Webcast

Cepheid (Nasdaq: CPHD) today announced that it will report financial results for its 2014 third quarter ended September 30, 2014 on Thursday,...

Sep 04, 2014, 07:00 ET

Cepheid Recognized as Innovation Leader

 Cepheid (NASDAQ: CPHD) today announced that it has been named to Forbes magazine's list of the World's Most Innovative Growth Companies,...

Sep 03, 2014, 07:00 ET

Cepheid Announces European Release of Xpert TV, a Next-Generation Molecular Test for Rapid and Accurate Identification of Trichomonas vaginalis Infections

 Cepheid (NASDAQ: CPHD) today announced the release of Xpert® TV, an on-demand molecular test for rapid, accurate and reproducible...

Sep 02, 2014, 07:00 ET
Influenza: Evolution in Action. (PRNewsFoto/Cepheid)

Cepheid Announces European Release of Xpert Flu/RSV XC for Accurate and Reliable Detection and Differentiation of Flu A, Flu B, and RSV Infection

Cepheid (NASDAQ: CPHD) announced today the release of Xpert® Flu/RSV XC, an on-demand molecular test for rapid, accurate and reliable...

Jul 31, 2014, 16:05 ET

Cepheid to Webcast Upcoming Financial Presentations

 Cepheid (NASDAQ: CPHD) today announced that its executives will be speaking at the following conferences, and invited investors to participate...

Jul 30, 2014, 16:05 ET

Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement

 Cepheid (Nasdaq: CPHD) today announced that its group purchasing contract with Premier will end on September 30, 2014.  Customers...